(Press-News.org)
The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people. The drug has long been marketed in Japan for another use: improving blood lipid levels in patients with hyperlipidaemia, a common condition in diabetics. Now, however, it could help address this serious liver disease, which still has no specific treatment.
The study, carried out on laboratory animal models and published in the journal Biomedicine & Pharmacotherapy, was conducted by a team led by Professor Juan Carlos Laguna, from the UB’s Faculty of Pharmacy and Food Sciences, the UB Institute of Biomedicine (IBUB) and the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBEROBN). The study has been carried out in collaboration with the research group of Professor Conxita Amat, from the Department of Biochemistry and Physiology of the same UB faculty, and the UB’s Nutrition and Food Safety Research Institute (INSA-UB), based at the Torribera Food Campus.
Drug repurposing: a new life for medicines
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition formerly known as non-alcoholic fatty liver disease. It is a multisystem disorder, with a very heterogeneous origin and a diverse course that can degenerate into cirrhosis, liver cancer or liver failure. It usually has no clear symptomatology and the early stages can last for decades.
Today, pemafibrate is used to treat alterations in blood cholesterol and triglyceride levels (dyslipidaemia). According to the new paper, it could also open a new therapeutic avenue to address MASLD in the context of drug repositioning, i.e. the use of known and approved drugs in clinical practice to treat other pathologies. This strategy makes it possible to fully exploit the therapeutic potential of drugs and thus reduce the time and economic costs of bringing another drug to market to treat diseases without effective therapy.
“The common pathological manifestation of MASLD is hepatic steatosis (fatty liver disease, or SLD). Although it can be reversed with lifestyle changes, diet and exercise, in practice it is difficult to control and there are no specific drugs to treat it. The repositioning of drugs with a good safety profile for clinical use in other pathologies is an optimal approach to finding new treatments”, says Professor Juan Carlos Laguna, from the Department of Pharmacology, Toxicology and Therapeutic Chemistry.
In an experimental model of SLD in female rats, pemafibrate prevents the development of hepatic steatosis, increases fatty acid catabolism and cholesterol clearance in the liver, and shows a good safety profile. As the preclinical study was conducted in female rats, the findings could also help to identify sex differences in the physiology of chronic diseases and thus reduce gender bias in biomedical research.
“Pemafibrate is a new modulator of the transcriptional activity of the nuclear receptor PPAR-α (peroxisome proliferator-activated receptor alpha), which increases the hepatic oxidation of fatty acids, necessary for the synthesis of triglycerides and cholesterol esters — which accumulate pathologically in the liver in SLD — and also for bile acids, which favours the elimination of cholesterol from the body”, the researcher explains.
These results suggest that pemafibrate is a good candidate for therapeutic repositioning to treat SLD. “To our knowledge, this drug has not been used in the context of pharmacological repositioning, apart from a few exploratory clinical studies on its effects in liver pathology. Now we want to study its efficacy and safety in experimental models of more advanced liver disease, with the presence of inflammation and fibrosis in metabolic associated steatohepatitis (MASH)”, concludes Professor Laguna.
END
NEW ORLEANS – Ochsner Health’s Healthy State initiative, in partnership with The American Journal of Managed Care, will host a free conference on value-based care from 3:30-7 p.m. on Thursday, July 25 at The Westin New Orleans hotel in Louisiana.
Registration and program details are available here for “Healthy State: Know It, Own It, Live It: Creating a Thriving Louisiana Through Innovation in Value-Based Care.” The event is open to the public, medical professionals, health policy experts and community organizers.
Organized ...
A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB). Investigators at the University of California, San Francisco; Johns Hopkins Medicine; and Vanderbilt University Medical Center comprise the other co-leads.
The Preclinical Design and Clinical Translation ...
Women over the age of 65 who require complex heart surgery are more likely than men to receive care at low quality hospitals — where they also die in greater numbers following the procedure, a Michigan Medicine study finds.
The research, published in JAMA Network Open, covered nearly 450,000 Medicare beneficiaries who underwent coronary artery bypass grafting, or heart bypass surgery, between late 2015 and early 2020.
Compared to men, women were 1.26 times more likely to be treated at low quality hospitals, meaning facilities with the highest 30-day mortality rates.
At those low quality hospitals, ...
Vehicle exhaust from fossil fuel combustion constitutes a main source of air pollutants like carbon dioxide and carbon monoxide. To mitigate air pollution, researchers are looking into additive to fuels like dimethoxymethane (DMM). But DMM production brings its own environmental hazards.
In their paper published June 21 in Carbon Future, a Chinese research team demonstrated how a series of phosphorous-modified nanocarbon catalysts could advance green DMM production.
Unique fuel properties of this diesel blend fuel include high oxygen content and chemical stability as well as low toxicity. A blend of DMM and ...
FROM: James Urton
(Note: researcher contact information at the end)
Humans drove wolves to extinction in Washington state around the 1930s. Thanks to conservation efforts, by about 80 years later, wolves had returned — crossing first from the Canadian border into Washington around 2008 and later entering the state from Idaho. Since then, wolf numbers in Washington have been steadily growing, raising questions about what the return of this large predator species means for ecosystems and people alike.
In northeast Washington, where wolves have recovered most successfully, researchers from the University of Washington and the Washington Department ...
The Moon’s recent discovery of energy resources, such as water ice, has refocused interest on its potential as a sustainable hub for space exploration. NASA has also announced the Artemis mission, aiming for long-term human presence on the lunar surface. However, infrastructure expansion, such as lunar base construction plays a vital role.
Yet, transporting construction materials from Earth to the lunar surface via landers incurs a significant cost of 1.2 million USD per kilogram. Weight directly translates to cost, making the transportation of construction materials from Earth to the Moon nearly impossible.
To solve this problem, Korea ...
A smartphone’s unique Bluetooth fingerprint could be used to track the device’s user–until now. A team of researchers have developed a simple firmware update that can completely hide the Bluetooth fingerprint, eliminating the vulnerability.
The method was developed by a team of researchers at the University of California San Diego. The team discovered the vulnerability caused by Bluetooth fingerprints in a study they presented at the 2022 IEEE Security & Privacy conference. They presented the fix to this vulnerability two years later at the 2024 IEEE Security & Privacy conference. The math behind the update itself is complex but the implementation ...
Ischemic heart disease stands as a significant global cause of morbidity and mortality. One promising avenue for treatment involves human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs). Derived from adult somatic cells such as blood or skin cells, hiPS cells possess the capacity to differentiate into various tissues, including cardiomyocytes. These cells can potentially repair damaged heart tissue, but their clinical application is limited due to concerns about immune rejection. Understanding the immunogenicity of hiPS-CMs is crucial for advancing their ...
Overproduction of Group 2 innate lymphoid cells or ILC2s—a type of white blood cells—can sometimes exacerbate conditions such as bronchial asthma, chronic rhinosinusitis, atopic dermatitis, and organ fibrosis through an exaggerated immune response. Although there are immunomodulatory drugs that can suppress Type 2 helper T (Th2) cells, drugs capable of suppressing ILC2s are currently lacking.
Now, however, in a breakthrough study that could lead to the development of a new therapeutic strategy targeting ILC2s, researchers led by Associate Professor Arifumi Iwata of the Chiba University Hospital, Japan, have identified molecular ...
The Specialised Group on Chemistry of Natural Products (GQPN) of the Spanish Royal Society of Chemistry (RSEQ) has awarded its Excellence in Research Award 2023 to Professor Ricardo Riguera. The Evaluation Committee thus recognises his valuable contribution to this area of chemistry. Among other advances, his work has made it possible to describe a large number of bioactive metabolites, such as the first heptacyclopeptide and the first cyclodepsipeptide isolated from marine organisms. Riguera also identified one of the first examples of cytotoxic metabolites from marine bacteria, the first description of L-galactose as part of a natural product, and the first description ...
